Company
ASX:1AD
AdAlta is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers. The company's “East to West” cellular immunotherapy strategy is the primary driver of future growth and value creation initiatives.
45 stories · page 3 of 3
“This second patent strengthens AdAlta’s patent portfolio and in particular provides protection for AD-214 in one of the largest pharmaceutical and pulmonary fibrosis markets in the world. Strong intellectual property protection is essentia
The clinical-stage drug development company aims to use its unique i-body technology to create multiple novel therapeutics for debilitating diseases that have proven difficult to drug with traditional antibodies.
The clinical-stage drug development company is using its proprietary i-body technology to solve challenging drug targeting problems and generate a promising new class of single-domain antibody protein therapeutics with the potential to trea
The i-body technology platform of AdAlta is initially focused on treating fibrotic diseases, such as IPF.
Idiopathic Pulmonary Fibrosis (IPF) is an irreversible, unpredictable and incurable disease.
